AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 301 min read$ABEO

Seshadri Vishwas sold $101K of ABEO

Seshadri Vishwas (Chief Executive Officer) sold 19,608 shares of ABEONA THERAPEUTICS INC. (ABEO) at $5.16 ($0.10M total) on 2026-09-29.

Original reporting
SEC EDGAR · Seshadri Vishwas
Published Sep 30, 2026, 1:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 2:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABEO
Bearish
medium confidence
Mentioned
$ABEO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABEOBearishLow
01

Why it matters

The disclosed sale is modest in size but provides fresh information about insider behavior, offering a slight bearish cue.

02

Market read

The filing adds a new data point for traders monitoring insider activity at ABEO, but the small transaction limits its market impact.

03

What to watch

Potential upcoming clinical data releases or partnership announcements could offset the negative signal from the sale.

Relevance 4/10Novelty 5/10Timing: post-market today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$ABEOBearishMedium confidence
Context

CEO Seshadri Vishwas sold 19,608 shares for $101,091 on 2026-09-29.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A $101k sale by the CEO is a primary disclosure but the amount is modest; traders may view it as a slight negative signal.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are common and unlikely to shift sector sentiment.

Regional

No significant regional effect; the filing is specific to ABEO.

Global

Limited global relevance; only relevant to investors tracking ABEO.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals, so price impact may be negligible.

Key entities

  • Company
    Abeona Therapeutics Inc.

    US-listed biotech company (ticker ABEO).

  • Executive
    Seshadri Vishwas

    Chief Executive Officer of Abeona Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABEO insider trading history →

Related articles

SEP 26
$ABEOMed

Abeona, NexGen, Nano Nuclear, SanDisk, Tempus Trending

Analysts initiated coverage on five stocks: Abeona (ABEO) with a $17 target, NexGen (NXE) at $14, Nano Nuclear (NNE) at $33, SanDisk (SNDK) at $2,400, and Tempus (TEM) at $75. Abeona's ZEVASKYN gene therapy, NexGen's uranium project, Nano Nuclear's KRONOS reactor, SanDisk's AI infrastructure, and Tempus's diagnostics business are key focuses.

tipranks.com3 min
SEP 18
$ABEOHighAI 9/10

Abeona Therapeutics Inc.: Abeona Therapeutics Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Abeona Therapeutics (ABEO) congratulated Ultragenyx (RARE) on FDA approval of FAYUVI, a gene therapy for Sanfilippo syndrome type A (MPS IIIA). Abeona initially developed the therapy and licensed it to Ultragenyx in 2022, making it eligible for milestone payments and royalties. FAYUVI addresses a rare, progressive neurodegenerative disease with high unmet medical need.

finanznachrichten.de2 min
AUG 13
$ABEOMed

Abeona Therapeutics Swings To Q2 Net Loss; Shares Plunge

Abeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.

rttnews.com4 min